ASX:1AD AdAlta (1AD) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free 1AD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume135,957 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AdAlta alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About AdAlta Stock (ASX:1AD)AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. 1AD Stock News HeadlinesApril 29, 2024 | msn.comAdAlta locks in $3.7m to speed up Phase II clinical trials, near-term partnershipsApril 8, 2024 | msn.comLong Shortz with AdAlta: Strengthening bonds in the fight against cancerMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 7, 2024 | msn.comAdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapyMarch 8, 2024 | finance.yahoo.comAdAlta delivers positive Phase I Extension Study results for AD-214March 8, 2024 | msn.comScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial resultsFebruary 15, 2024 | bbc.comLeeds - Weather warnings issuedFebruary 11, 2024 | msn.comCountdown on to AdAlta trial results as biotech advances partner discussionsMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...February 4, 2024 | finance.yahoo.comAdAlta Insiders Placed Bullish Bets Worth AU$850.2kJanuary 22, 2024 | msn.comAdAlta advancing partnering programs as AD-214 participants receive final doseJanuary 9, 2024 | es.investing.comAdalta Ltd (1AD)January 4, 2024 | msn.comWhat’s in store for 2024: AdAltaDecember 28, 2023 | msn.comMoney Talks: Keep an eye on these tasty precious metal and biotech plays in 2024December 19, 2023 | msn.comLong Shortz with AdAlta: How the company has potentially broken the malaria life cycleDecember 18, 2023 | msn.com‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatmentDecember 13, 2023 | msn.comAdAlta on track for trial readout in Q1 2024 after $1.65m cap raiseNovember 30, 2023 | msn.com‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024November 20, 2023 | msn.comASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra HealthNovember 20, 2023 | msn.comAdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risksNovember 18, 2023 | proactiveinvestors.com.auAdAlta raises $1.65 million in oversubscribed placement to support clinical study and partner discussionsNovember 15, 2023 | finance.yahoo.comIt's Probably Less Likely That AdAlta Limited's (ASX:1AD) CEO Will See A Huge Pay Rise This YearNovember 7, 2023 | proactiveinvestors.com.auAdAlta closes oversubscribed $1.65 million raiseOctober 22, 2023 | proactiveinvestors.com.auAdAlta making material progress on partnering talksOctober 19, 2023 | au.investing.comAdAlta to present lead product AD-214 at MPGPCR 2023 pharmacology conferenceOctober 17, 2023 | proactiveinvestors.com.auAdAlta receives $2.3 million FY23 R&D refund; extends loan repayment termsSeptember 26, 2023 | finance.yahoo.comAdAlta says new AD-214 dosing models enhance partnering potentialSee More Headlines Receive 1AD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AdAlta and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:1AD CUSIPN/A CIKN/A Webwww.adalta.com.au Phone61 3 9479 5159FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,040,000.00 Net Margins-144.13% Pretax MarginN/A Return on Equity-196.58% Return on Assets-48.37% Debt Debt-to-Equity Ratio82.91 Current Ratio1.83 Quick Ratio2.84 Sales & Book Value Annual Sales$3.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.94 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares525,810,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.67 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Timothy Charles Oldham B.Sc.BSc(Hons), L.L.B., LLB(Hons), Ph.D., CEO, MD & DirectorMr. Angus Tester Ph.D.Senior Director of OperationsMs. Janette DixonHead of Business DevelopmentMr. Cameron Jones C.A.Company SecretaryKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersRobert PeachSold 1,750,000 sharesTotal: $22,750.00 ($0.01/share)David FullerSold 210,668 sharesTotal: $5,056.03 ($0.02/share) 1AD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of AdAlta own? Based on aggregate information from My MarketBeat watchlists, some companies that other AdAlta investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), iRhythm Technologies (IRTC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT). This page (ASX:1AD) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Nvidia. This is the future of AIPorter & CompanyHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdAlta Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
